<DOC>
	<DOC>NCT01647789</DOC>
	<brief_summary>This study will assess the safety and preliminary antitumor activity of CFG920, a new CYP17 inhibitor in castration resistant prostate cancer patients who are abiraterone naive or abiraterone resistant.</brief_summary>
	<brief_title>A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Confirmed diagnosis of castration resistant prostate cancer Documented metastases ECOG performance status 0 or 1 Documented progression following the Prostate Cancer Working Group 2 guidelines Fresh or archived tumor sample Impaired cardiac function Uncontrolled hypertension despire appropriate medical therapy History of pituitary or adrendal dysfunction Chronic steriod therapy other than daily use of 10mg prednisone Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of oral CFG920 Brain metastases that have not been adequately treated Malignant disease other than that being treated in this study Laboratory abnormalities as specified in the protocol Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>prostate cancer, castration resistant,</keyword>
</DOC>